RxTrials Institute Drug Pipeline Alert
March 19, 2008 | Vol. 6 No. 12
Pharma Blog Watch
Approvable Letter for MRSA Treatment (Eye on FDA)
“According to the company, prior to approval the FDA wants ‘completion and assessment of clinical study site inspections, assessment of clinical and microbiological data provided but not yet reviewed, and further characterization of patients with diabetic foot infections,’” Senak writes.
The product also is under review in Canada, Switzerland and the European Union. Johnson & Johnson, Basilea’s partner, has not issued a release.
“According to CNN Money, shares of Basilea dropped 25 percent at the news,” Senak writes.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.